← All trials
NCT03829436
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2019
- Primary completion
- Feb 18, 2022
- Completion date
- Jun 23, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 338
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tempest TherapeuticsLead sponsor
- Tempest TherapeuticsStudy director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Pancreatic Neoplasms
- Sarcoma
- Colorectal Neoplasms
- Cholangiocarcinoma
- Prostatic Neoplasms, Castration-Resistant
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.